Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5780-5789

  Driscoll, Timothy A ^a   Frangoul, Haydar ^b   Nemecek, Eneida R ^c   Murphey, Donald K ^d   Yu, Lolie C ^e   Blumer, Jeffrey ^f   Krance, Robert A ^g   Baruch, Alice ^h   Liu, Ping ^h  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Risk Evaluation to Achieve Cardiovascular Health   (United States)

^e CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g TEXAS CHILDREN S HOSPITAL   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; BODY WEIGHT; BONE PAIN; CHILD; CLINICAL ARTICLE; COLOR BLINDNESS; CONJUNCTIVITIS; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRY EYE; DYSURIA; FEMALE; FEVER; FLUID RETENTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; KIDNEY FAILURE; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; NAUSEA; OXYGEN SATURATION; PHOTOPHOBIA; PRIORITY JOURNAL; QT PROLONGATION; RASH; SCHOOL CHILD; SIDE EFFECT; VISUAL IMPAIRMENT; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 81555208497     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05010-11     Document Type: Article

References (16)

1. Andrews, E., et al. 2008. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br. J. Clin. Pharmacol. 65:531-539. (Pubitemid 351365140)
2. Clancy, C. J., and M. H. Nguyen. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575. (Pubitemid 28464363)
3. Denning, D. W., et al. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571. (Pubitemid 34165316)
4. Driscoll, T. A., et al. 2011. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob. Agents Chemother. 55:5770-5779.
5. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202. (Pubitemid 28047458)
6. Espinel-Ingroff, A., K. Boyle, and D. J. Sheehan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115. (Pubitemid 32623880)
7. Michael, C., et al. 2010. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob. Agents Chemother. 54:3225-3232.
8. Neely, M., T. Rushing, A. Kovacs, R. Jelliffe, and J. Hoffman. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
9. Pascual, A., et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
10. Perfect, J. R., et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
11. Pfizer Inc. 2010. VFEND® (voriconazole) United States package insert. Pfizer Inc., New York, NY.
12. Purkins, L., et al. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553. (Pubitemid 34793462)
13. Smith, J., and D. Andes. 2008. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit. 30:167-172. (Pubitemid 351521643)
14. Smith, J., et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
15. Walsh, T. J., et al. 2010. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob. Agents Chemother. 54:4116-4123.
16. Walsh, T. J., et al. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172. (Pubitemid 38691615)